In this regard, the CCR5-antagonist maraviroc, already licensed by the US Food and Drug administration for HIV treatment, may be repurposed for cHL based on pre-clinical data showing inhibition of monocyte recruitment and shrinkage of tumor masses in vivo [24]. This evidence concerns the gene CCR5 and classic Hodgkin lymphoma.